Trifecta Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Trifecta Capital Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.52K	Hold	155	–	–	﹤0.01%	263
2026 Q1	$4.1K	Hold	155	–	–	﹤0.01%	250
2025 Q4	$4.49K	Hold	155	–	–	﹤0.01%	243
2025 Q3	$4.3K	Hold	155	–	–	﹤0.01%	275
2025 Q2	$3.77K	Sell	155 -310	-67%	-$6.79K	﹤0.01%	282
2025 Q1	$9.65K	Hold	465	–	–	﹤0.01%	216
2024 Q4	$10.9K	Hold	465	–	–	﹤0.01%	209
2024 Q3	$11.9K	Hold	465	–	–	﹤0.01%	211
2024 Q2	$10.9K	Hold	465	–	–	﹤0.01%	213
2024 Q1	$13.4K	Hold	465	–	–	﹤0.01%	193
2023 Q4	$15.3K	Hold	465	–	–	﹤0.01%	187
2023 Q3	$13K	Hold	465	–	–	﹤0.01%	200
2023 Q2	$15.9K	Hold	465	–	–	0.01%	190
2023 Q1	$14K	Hold	465	–	–	﹤0.01%	200
2022 Q4	$13.1K	Buy	+465	New	+$14.8K	0.01%	183

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Trifecta Capital Advisors's ARKG Position: Q2 2026 in Review

Trifecta Capital Advisors held its ARK Genomic Revolution ETF (ARKG) position steady in Q2 2026 at 155 shares worth $6.52K. The position accounts for ﹤0.01% of the portfolio, ranked #263.

Trifecta Capital Advisors first reported a position in ARKG in Q4 2022 and has held it in 15 quarters since. The position peaked at $15.9K in Q2 2023. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Trifecta Capital Advisors held 155 shares of ARK Genomic Revolution ETF worth $6.52K as of Q2 2026.
Trifecta Capital Advisors left its ARK Genomic Revolution ETF share count unchanged in Q2 2026.
ARK Genomic Revolution ETF made up ﹤0.01% of Trifecta Capital Advisors's portfolio in Q2 2026, its #263 holding.
Trifecta Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2022 and has held it in 15 quarters since.
Trifecta Capital Advisors's ARK Genomic Revolution ETF position peaked at $15.9K in Q2 2023.
271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Trifecta Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.